TY - JOUR
T1 - Development of a drug assay system with hepatitis C virus genome derived from a patient with acute hepatitis C
AU - Mori, Kyoko
AU - Ueda, Youki
AU - Ariumi, Yasuo
AU - Dansako, Hiromichi
AU - Ikeda, Masanori
AU - Kato, Nobuyuki
N1 - Funding Information:
Acknowledgment This study was supported by grants-in-aid for research on hepatitis from the Ministry of Health, Labor, and Welfare of Japan. K. M. was supported by a Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science.
Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2012/6
Y1 - 2012/6
N2 - We developed a new cell culture drug assay system (AH1R), in which genome-length hepatitis C virus (HCV) RNA (AH1 strain of genotype 1b derived from a patient with acute hepatitis C) efficiently replicates. By comparing the AH1R system with the OR6 assay system that we developed previously (O strain of genotype 1b derived from an HCV-positive blood donor), we demonstrated that the anti-HCV profiles of reagents including interferon-γ and cyclosporine A significantly differed between these assay systems. Furthermore, we found unexpectedly that rolipram, an anti-inflammatory drug, showed anti-HCV activity in the AH1R assay but not in the OR6 assay, suggesting that the anti-HCV activity of rolipram differs depending on the HCV strain. Taken together, these results suggest that the AH1R assay system is useful for the objective evaluation of anti-HCV reagents and for the discovery of different classes of anti-HCV reagents.
AB - We developed a new cell culture drug assay system (AH1R), in which genome-length hepatitis C virus (HCV) RNA (AH1 strain of genotype 1b derived from a patient with acute hepatitis C) efficiently replicates. By comparing the AH1R system with the OR6 assay system that we developed previously (O strain of genotype 1b derived from an HCV-positive blood donor), we demonstrated that the anti-HCV profiles of reagents including interferon-γ and cyclosporine A significantly differed between these assay systems. Furthermore, we found unexpectedly that rolipram, an anti-inflammatory drug, showed anti-HCV activity in the AH1R assay but not in the OR6 assay, suggesting that the anti-HCV activity of rolipram differs depending on the HCV strain. Taken together, these results suggest that the AH1R assay system is useful for the objective evaluation of anti-HCV reagents and for the discovery of different classes of anti-HCV reagents.
KW - Acute hepatitis C
KW - Anti-HCV activity of rolipram
KW - Anti-HCV drug assay system
KW - HCV
UR - http://www.scopus.com/inward/record.url?scp=84863718301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863718301&partnerID=8YFLogxK
U2 - 10.1007/s11262-012-0712-2
DO - 10.1007/s11262-012-0712-2
M3 - Article
C2 - 22252251
AN - SCOPUS:84863718301
SN - 0920-8569
VL - 44
SP - 374
EP - 381
JO - Virus Genes
JF - Virus Genes
IS - 3
ER -
